BrePco Biopharma is pleased to announce that Neoatricon® – Dopamine Hydrochloridefor Infusion, is now available in Germany.
About Neoatricon®
Neoatricon® is a critical inotropic and vasopressor agent and is the only formulation of Dopamine Hydrochloride approved for the treatment of hypotension in Neonates, Infants and Children under 18 years of age.
The availability of an age-appropriate formulation of this drug improves safety compared to off-label use of adult-approved drug. Critical improvements include ensuring of precise dosing, minimizing preparation time in neonatal and paediatric intensive care units (NICU & PICU), facilitating faster intervention in emergency settings, and reducing the risk of microbial ingress into the preparation.
Neoatricon® is a ready to use formulation with no dilution required
Available in 1.5 mg/mL 30 mL vial and 4.5 mg/mL 50 mL for flexible dosing.
Neoatricon® is a registered trademark owned by BrePco Biopharma Limited, Ireland.